Zimulti Loses On Weight Loss; Sanofi May Try Diabetes Route To Get Approval
Executive Summary
If FDA concurs with the Endocrinologic and Metabolic Drugs Advisory Committee's negative opinion of the pending obesity indication for Zimulti (rimonabant), Sanofi-Aventis may have another attempt at bringing the drug to market for type 2 diabetes
You may also be interested in...
FDA Gives Metabolism/Endocrinology Division An Acting Director
Diabetes team leader Jean-Marc Guettier is detailed to replace Mary Parks as director of the Division of Metabolism and Endocrinology Products on a temporary basis as she moves up to Deputy Director of the Office of Drug Evaluation II.
GSK’s Garnier Touts “Progressive Blockbuster” As Model For Future Drugs
One way to handle an increasingly cautious FDA would be to take a different tack on development - pursuing "progressive blockbusters" that are approved on a population-by-population basis to prove the drugs are safe in different patient types rather than trying to make a traditional blockbuster big splash, according to GlaxoSmithKline CEO JP Garnier
GSK’s Garnier Touts “Progressive Blockbuster” As Model For Future Drugs
One way to handle an increasingly cautious FDA would be to take a different tack on development - pursuing "progressive blockbusters" that are approved on a population-by-population basis to prove the drugs are safe in different patient types rather than trying to make a traditional blockbuster big splash, according to GlaxoSmithKline CEO JP Garnier